Lab Information

Inés Colmegna (MD)

Scientist
Centre for Translational Biology
Department of Medicine (McGill)

Research Profile

 Fundamental: 100%
 Clinical: 0%
 Epidemiology: 0%
 Evaluation: 0%
 This email address is being protected from spambots. You need JavaScript enabled to view it.

Keywords

Rheumatology • arthritis • vaccine responses in rheumatology patients • stem and progenitor cells • aging • immunology

Research Interests

My research focuses on evaluating the mechanisms underlying the development and perpetuation of the most common form of inflammatory polyarthritis: rheumatoid arthritis. Specifically, my group studies the impact of aging on human immune and stem/progenitor cell function. This will help in understanding the interplay of aging with immune tolerance and the risk of developing autoimmune disorders. In addition, we are interested in evaluating how protective responses generated by vaccines can be enhanced in people with rheumatologic conditions. This will help in reducing the morbidity and mortality of vaccine preventable diseases in this vulnerable group.


Team Members

Name Position

Latest Publications

  1. Baniña, M. C., Prabhune, R., Charles, C., Colmegna, I., Hudson, M., Bernatsky, S. & Peláez, S. (2025). Understanding patient and physician perspectives regarding innovative research in rheumatoid arthritis. The Journal of rheumatology.
  2. Ye, C., Nikolic, R. P. A., Choi, M., Fifi-Mah, A. V., Graham, J., O'Neil, L. J., Kobza, A., Lau, K. C. K., Arreola, L. G., Pardo Pardo, J., Ladouceur, A., Saltman, A., Velthuizen, D., Khokhar, F., Colmegna, I., Pope, J. E., Roberts, J., Hudson, M., Himmel, M., Maltez, N., Hoa, S., Hazlewood, G. S. & Jamal, S. (2025). Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 2: Preexisting Systemic Autoimmune Rheumatic Diseases. The Journal of rheumatology.
  3. Ye, C., Nikolic, R. P. A., Choi, M., Fifi-Mah, A. V., Graham, J., O'Neil, L. J., Kobza, A., Lau, K. C. K., Arreola, L. G., Pardo Pardo, J., Ladouceur, A., Saltman, A., Velthuizen, D., Khokhar, F., Colmegna, I., Pope, J. E., Roberts, J., Hudson, M., Himmel, M., Maltez, N., Hoa, S., Hazlewood, G. S. & Jamal, S. (2025). Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 1: Preexisting Inflammatory Arthritides. The Journal of rheumatology.
  4. Aw, M., Lee, T. C., Mendel, A. & Colmegna, I. (2025). Parvovirus B19-Associated Large-Vessel Vasculitis in an Immunocompromised Patient. The Journal of rheumatology.
  5. Nguyen, N., Bernatsky, S., Colmegna, I., Berger, C., Carrier, N., Allard-Chamard, H., Liang, P., Roux, S., Boire, G. & Hudson, M. (2025). Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Using an Extended Set of Clinical Variables: An Unmet Need. International journal of rheumatic diseases, vol. 28, p. e70281.
  6. Hitchon, C. A., Scuccimarri, R., Colmegna, I., Masaisa, F., Mody, G. M., Meltzer, M. & Rheumatology For All Rwanda Program Group (2025). Implementation and evaluation of a virtual rheumatology training program in East Africa. The Journal of rheumatology, vol. 52, p. 1043-1049.
  7. Lora, M., Ménard, H. A., Nijnik, A., Langlais, D., Hudson, M. & Colmegna, I. (2025). Low Dose Methotrexate Has Divergent Effects on Cycling and Resting Human Hematopoietic Stem and Progenitor Cells. Clinical and translational science, vol. 18, p. e70233.
  8. Tan, J., Bernatsky, S., Lee, J. L. F., Fortin, P. R., Dayam, R. M., Gingras, A.-C., Colmegna, I., Bowdish, D. M. E., Berger, C., Chan, D., Larché, M. J., Richards, D. P., Gonzalez Arreola, L., Hitchon, C. A., Lalonde, N. & Aviña-Zubieta, J. A. (2025). COVID-19 Breakthrough Infections in Immune-Mediated Inflammatory Diseases: Data from the SUCCEED (Safety and Immunogenicity of COVID-19 Vaccines in Systemic Autoimmune-Mediated Inflammatory Diseases) Study. Vaccines, vol. 13.
  9. Ladouceur, A., Jamal, S., Saltman, A., Himmel, M., Hudson, M., Pope, J., Hoa, S., Roberts, J., Colmegna, I., Arreola, L. G., Nevskaya, T., Karmali, A., Moon, D., Schmidt, E., Toban, N., Cho, L., Barnetche, T. & Ye, C. (2025). Chronicity of Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis After Immunotherapy Discontinuation: Results From the Canadian Research Group of Rheumatology in Immuno-Oncology Database. ACR open rheumatology, vol. 7, p. e70002.
  10. Lu, J., Vulesevic, B., Burchell, A. N., Singer, J., Needham, J., Yang, Y., Qian, H., Chambers, C., Samji, H., Colmegna, I., Del Canto, S., Godin, G.-H., Habanyama, M., Hui, S. S. C., Kroch, A., Mandarino, E., Margolese, S., Martin, C., Owino, M., Lau, E., Mohammadi, T., Zhang, W., Pelaez, S., Kovacs, C., Benko, E., Cooper, C. L., Anis, A. H., Costiniuk, C. T. & COVAXHIV Study Group (2024). Sex differences in COVID-19 vaccine confidence in people living with HIV in Canada. Vaccine: X, vol. 21, p. 100566.
More on PubMed 



See also

Card image
Sasha
Bernatsky


See profile
Card image
Elizabeth
Hazel


See profile
Card image
Brian
Ward


See profile
Card image
Arielle
Mendel


See profile
Card image
Cecilia
Costiniuk


See profile
Card image
Évelyne
Vinet


See profile